Search research articles
Contact Us
Filters
Showing results (1-10 of 159) with videos related to
Page
of 16
Sort By:
Oncotarget
|
January 17, 2015
Advances in targeted therapies and new promising targets in esophageal cancer
Abbes Belkhiri, Wael El-Rifai
Gut
|
July 2, 2013
5-Methylcytosine hydroxylation-mediated LINE-1 hypomethylation: a novel mechanism of proto-oncogenes activation in colorectal cancer?
Abbes Belkhiri, Wael El-Rifai
Gastroenterology
|
July 12, 2011
DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib
Shoumin Zhu, Abbes Belkhiri, Wael El-Rifai
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|
September 20, 2008
Therapeutic prospects for p73 and p63: rising from the shadow of p53
Anna Vilgelm, Wael El-Rifai, Alexander Zaika
Oncotarget
|
February 13, 2016
DARPP-32: from neurotransmission to cancer
Abbes Belkhiri, Shoumin Zhu, Wael El-Rifai
Gastroenterology
|
November 18, 2022
Reply
Mohammed Soutto, Xing Zhang, Wael El-Rifai
Gastroenterology
|
June 27, 2022
Reply
Longlong Cao, Heng Lu, Wael El-Rifai
Molecular Cancer
|
May 20, 2015
Aurora kinase A in gastrointestinal cancers: time to target
Ahmed Katsha, Abbes Belkhiri, Laura Goff, et al.
Redox Biology
|
February 23, 2021
The antioxidant response in Barrett's tumorigenesis: A double-edged sword
Dunfa Peng, Alexander Zaika, Jianwen Que, et al.
Cancer Research
|
September 18, 2004
p73 isoforms can induce T-cell factor-dependent transcription in gastrointestinal cells
Katarina Tomkova, Abbes Belkhiri, Wael El-Rifai, et al.
Page
of 16
Search research articles
Search
Showing results (1-10 of 159) with videos related to
Sort By:
Page
of 16
Oncotarget
|
January 17, 2015
Advances in targeted therapies and new promising targets in esophageal cancer
Abbes Belkhiri, Wael El-Rifai
Gut
|
July 2, 2013
5-Methylcytosine hydroxylation-mediated LINE-1 hypomethylation: a novel mechanism of proto-oncogenes activation in colorectal cancer?
Abbes Belkhiri, Wael El-Rifai
Gastroenterology
|
July 12, 2011
DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib
Shoumin Zhu, Abbes Belkhiri, Wael El-Rifai
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|
September 20, 2008
Therapeutic prospects for p73 and p63: rising from the shadow of p53
Anna Vilgelm, Wael El-Rifai, Alexander Zaika
Oncotarget
|
February 13, 2016
DARPP-32: from neurotransmission to cancer
Abbes Belkhiri, Shoumin Zhu, Wael El-Rifai
Gastroenterology
|
November 18, 2022
Reply
Mohammed Soutto, Xing Zhang, Wael El-Rifai
Gastroenterology
|
June 27, 2022
Reply
Longlong Cao, Heng Lu, Wael El-Rifai
Molecular Cancer
|
May 20, 2015
Aurora kinase A in gastrointestinal cancers: time to target
Ahmed Katsha, Abbes Belkhiri, Laura Goff, et al.
Redox Biology
|
February 23, 2021
The antioxidant response in Barrett's tumorigenesis: A double-edged sword
Dunfa Peng, Alexander Zaika, Jianwen Que, et al.
Cancer Research
|
September 18, 2004
p73 isoforms can induce T-cell factor-dependent transcription in gastrointestinal cells
Katarina Tomkova, Abbes Belkhiri, Wael El-Rifai, et al.
Page
of 16